Among patients receiving cART, giving prophylaxis until CD4 counts are more than 200 cells/mm3 was estimated to prevent 343 cases of primary PCP per 1000 patients, costing US$5100 per quality-adjusted life-year gained compared with no prophylaxis [13]. This evidence concerns the gene CD4 and pneumocystosis.